Patients enrolled into Phase III diabetic retinopathy drug trial

April 16, 2008

Vitreoretinal Technologies, Inc has begun to enrol and treat diabetic retinopathy patients in the clinical trial for its pharmaceutical treatment Vitreosolve.

Vitreoretinal Technologies, Inc has begun to enrol and treat diabetic retinopathy patients in the clinical trial for its pharmaceutical treatment Vitreosolve.

Vitreosolve, a small molecule currently used for vitreous liquefaction as an adjunct to pars plana vitrectomy surgery, is now being evaluated as a preventative treatment for diabetic retinopathy. There are currently no approved pharmaceutical treatments indicated for this condition.

The multinational Phase III trial, investigating safety and efficacy, is the first of two studies required for a New Drug Application (NDA) to be granted by the FDA. Patients are currently being enrolled and treated in India and the US.